HUB Organoids Merck Completes Acquisition of HUB Organoids Holding B.V., Expanding Next-Generation Biology Portfolio Merck, a global leader in science and technology, has finalized its acquisition of HUB Organoids Holding B.V. (HUB) after receiving regulatory approvals and meeting customary closing…
Trispecific WuXi Biologics a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a groundbreaking partnership with Candid Therapeutics, Inc. (“Candid”). Candid is a clinical-stage biotechnology firm aiming to lead advancements in T-cell engager therapies for autoimmune and…
HIV Testing WHO Launches Guideline Development Group to Establish New HIV Prevention and Testing Standards for Lenacapavir The World Health Organization (WHO) has announced the formation of a new Guideline Development Group (GDG) tasked with creating updated guidelines for the…
Revolution Medicines, a clinical-stage oncology company focused on developing targeted therapies for patients with RAS-addicted cancers, recently announced the successful closing of its upsized underwritten public offering. The offering comprised 16,576,088 shares of common stock, priced at $46.00 per share,…
Heart Disease: The Importance of Regular Health Screenings Care Access, a leading health Heart Disease and research company, is bringing its Heart & Kidney Health Screening initiative to Pearland, Texas. This effort aims to raise awareness about critical health risk…
Amid the growing global shortage of Pegasys® (peginterferon alfa-2a), PharmaEssentia (TWSE: 6446), a global biopharmaceutical company, is reaffirming its steadfast commitment to ensuring robust and reliable access to critical interferon therapies. The company’s response comes at a time when the…
WuXi AppTec Recognized for Its Continued Commitment to Environmental, Social, and Governance Excellence WuXi Biologics a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has proudly announced its inclusion in the 2024 Dow Jones Sustainability Indices (DJSI) for the…
The Future of Cancer Immunotherapy: Market Insights 2025-2029 The report titled “Cancer Immunotherapy Market 2025-2029 – Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant Guides” has been added to ResearchAndMarkets.com’s offerings. It aims to shed…
WuXi Biologics a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has entered a service agreement with Sino Biopharm, an innovative R&D-driven pharmaceutical group in China, to develop a first-in-class monoclonal antibody (mAb) targeting an undisclosed area. Under this…
ICON plc a leading global healthcare intelligence and clinical research organization, has received multiple prestigious awards in the second half of 2024, further solidifying its position as a top performer in the clinical research industry. For the second consecutive year,…
Colorectal Cancer Breakthrough: Bristol Myers Squibb Secures EC Approval for Opdivo + Yervoy in MSI-High mCRC Bristol Myers Squibb has announced that the Colorectal Cancer European Commission (EC) has approved the combination of Opdivo® (nivolumab) and Yervoy® (ipilimumab) as the…
Gilead Sciences, Inc and Terray Therapeutics, Inc. have entered into a strategic collaboration aimed at discovering and developing novel small molecule therapies across multiple therapeutic targets. This partnership leverages Terray’s cutting-edge tNova platform to accelerate drug discovery and deliver innovative…